- /
- Supported exchanges
- / US
- / SDGR.NASDAQ
Schrodinger Inc (SDGR NASDAQ) stock market data APIs
Schrodinger Inc Financial Data Overview
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Schrodinger Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Schrodinger Inc data using free add-ons & libraries
Get Schrodinger Inc Fundamental Data
Schrodinger Inc Fundamental data includes:
- Net Revenue: 269 M
- EBITDA: -127 765 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-11-04
- EPS/Forecast: -0.66
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Schrodinger Inc News
New
Schrödinger (SDGR) Stock Could Be Undervalued On Its 67% Run
Schrödinger has had a sharp reset over the past year, and the rally puts a spotlight on a simple question for anyone looking at the stock today. Do the company's actual and potential cash flows justi...
Is Schrödinger (SDGR) Still Below Fair Value After Strong Q3 Revenue Growth?
Schrödinger (SDGR) has drawn fresh attention after reporting third quarter 2026 results that showed higher sales and revenue, along with a narrower net loss over the first nine months of the year. I...
Raised Guidance Could Change The Case For Schrödinger Stock (SDGR)
Schrödinger reported third quarter 2026 revenue of US$64.49 million and a net loss of US$37.71 million, then raised full year 2026 guidance for annual contract value to a range of US$222 million to U...
Schrödinger outlines 2026 ACV of $222M-$232M while raising drug discovery revenue to $75M-$85M
Earnings Call Insights: Schrödinger (SDGR) Q3 2026 MANAGEMENT VIEW * "Our third quarter results reflect sustained commercial momentum and strong progress towards the long-range goals we outlined ...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.